Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
1923535
Knihovny.cz E-resources
- MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Gene Expression MeSH
- Genes, p53 * MeSH
- Immunohistochemistry MeSH
- Humans MeSH
- Antibodies, Monoclonal MeSH
- Mutation * MeSH
- Tumor Suppressor Protein p53 analysis genetics MeSH
- Neoplasms genetics pathology MeSH
- Antibodies MeSH
- Transfection MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antibodies, Monoclonal MeSH
- Tumor Suppressor Protein p53 MeSH
- Antibodies MeSH
Accumulation of the p53 protein was analysed in 212 human malignant lesions. Immunohistochemical staining with new polyclonal (CM-1) and monoclonal antibodies (BP 53-12 and BP53-24) to p53 on methacarn-fixed paraffin sections showed positive staining in 161 (76%). The positive tumours were found across a wide range of human malignancies including breast, colon, stomach, bladder and testis carcinomas, soft-tissue sarcomas and melanomas. The staining was always confined to the malignant lesion. Immunoprecipitation and quantitative ELISA assays established that the positive staining was associated with accumulation of the protein and that the protein was frequently in a mutant conformation. Accumulation of mutant p53 protein is therefore a common feature of human malignant disease.
